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Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and
mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory
bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here
we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and
antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness.
1. Introduction
Primary sclerosing cholangitis (PSC) is a chronic, fibro-
inflammatory, cholestatic liver disease of unknown etiopath-
ogenesis that affects children and adults worldwide [1–3].
PSC leads to end-stage cirrhosis, represents a major risk
factor for cholangiocarcinoma (CCA), and carries a median
liver transplant- (LT-) free survival of approximately 12
years [4–6]. Despite clinical trials of over fourteen different
pharmacologic agents, including but not limited to various
immunosuppressants and antifibrotics, medical therapy for
P S Ch a sy e tt ob ee s t a b l i s h e d[ 2]. Unlike in other cholestatic
liver diseases (e.g., primary biliary cirrhosis), treatment with
ursodeoxycholic acid (UDCA) has not been clearly shown to
have a beneficial effect in PSC [7]. In addition, high doses of
UDCAmaybeassociatedwithsignificantlygreaterincidence
of adverse outcomes [8]. Due to its progressive, idiopathic
nature and lack of medical therapy, PSC remains a leading
indication for liver transplantation in northern Europe and
the United States despite its relatively low prevalence (0.5–1.5
per 10,000) [9, 10]. Although operative treatment with liver
transplantation (LT) is effective for PSC, it is only performed
in specialty centers and in select patients; furthermore, even
in suitable LT candidates, PSC and CCA can recur post-LT
[11–13]. Therefore, given the morbidity and mortality of PSC
and the challenges associated with operative treatment, safe
and effective pharmacotherapies are critically needed.
PSC is now generally accepted as being a heterogeneous,
pathogenically complex disease, with genetic, immunologic,
environmental, and other potential factors being involved
[2,14].Therearenowseverallinesofevidencesuggestingthat
onesuchimportantandostensiblymodifiableetiopathogenic
factor is the microbiota, particularly enteric bacteria. Here
we provide a concise review on the molecular/cellular, trans-
lational, and clinical data regarding the possible role of the
microbiota in the pathogenesis of PSC and as a target of
pharmacologictherapyforpatientsafflictedwiththisdisease.
2. Primer on the Relationship between
PSC and the Gut
The association between PSC and the gut, most notably
inflammatory bowel disease (IBD), was first reported over
four decades ago [15, 16]. The geoepidemiology of IBD
among patients with PSC is heterogeneous; for example,
an estimated 75% of Western patients with PSC are (or
become) codiagnosed IBD (the majority of whom have2 BioMed Research International
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Figure1:Proposedconceptualmodelofprimarysclerosingcholangitis(PSC)etiopathogenesis.Cholangiocytesexistinamicroenvironment
abundant in potential etiologic mediators of cellular insult and activation, including microbial as well as nonmicrobial molecules. Whether
PSC etiopathogenesis is related to increased exposure to constitutive molecular mediators of injury (e.g., through the enterohepatic
circulation), alterations in the types of these mediators (e.g., due to enteric microbial dysbiosis), and/or an aberrant resident (e.g.,
cholangiocyte, hepatocyte) or recruited (e.g., lymphocyte) hepatic cell response remains uncertain. Immunogenetic factors can modify these
variables and thus play a role in modulating initiation and progression of biliary injury in PSC. CCA: cholangiocarcinoma; HLA: human
leukocyte antigen; NOD: nucleotide-binding oligomerization domain receptor; TLR: toll-like receptor.
ulcerativecolitis,UC)[1,17]ascomparedtoonly23%insome
cohorts of Japanese patients [18]. The PSC-IBD association
is thought to be related at least in part to the increased
intestinal permeability observed in some patients with IBD
[19–21] as well as the direct anatomic link between the gut
and the liver, that is, the enterohepatic circulation [14, 22].
Although the putative gut-derived trigger(s) of hepatobiliary
pathobiology in PSC has not been determined, microbial
metabolites or products (i.e., pathogen-associated molecular
patterns, PAMPs) such as lipopolysaccharide (i.e., endotoxin,
LPS) and peptidoglycan (i.e., a bacterial cell wall polymer,
PG) have been proposed as likely candidates [23, 24]. This
forms the basis of what has been referred to as the “leaky gut”
or “PSC microbiota” hypotheses (the latter not emphasizing
a need for increased intestinal permeability given some
patients with PSC who have no detectable bowel disease
and normal intestinal permeability) [23, 25, 26]. Indeed,
portalbacteremiaandbacteriobiliahavebothbeendescribed
in patients with PSC-IBD [27, 28]. However, the extent to
which the association between PSC and IBD is due to (i)
increased enterohepatic circulation of PAMPs, (ii) abnormal
PAMPs (e.g., as a result of enteric microbial dysbiosis, as
seen in IBD) [29–31], or (iii) an aberrant or hyperreactive
cholangiocyteand/orinnateimmuneresponse(i.e.,asaresult
of “immunogenetic susceptibility” [24, 32, 33]) to essentially
normal levels and repertoires of enterohepatically circulated
PAMPs (or other potential gut-derived molecules) remains
a key unknown; given the heterogeneity of PSC, it is possible
thatanyofthesethreepossibilitiesmaybeoperativeinagiven
patient (Figure 1)[ 2, 24].
3. Findings from Animal Models Supporting
the Gut-Hepatobiliary Disease Relationship
Several lines of experimental evidence from animal models
demonstrate that enteric dysbiosis and/or administration of
bacterial antigens can lead to hepatobiliary inflammation
with various features of PSC. Lichtman et al. were the first
to conduct a number of elegant studies in the early 1990s
demonstrating this relationship. For example, rats with small
bowel bacterial overgrowth as a result of surgically created
self-filling jejunal blind loops were found to have abnor-
malities of the extrahepatic and intrahepatic bile ducts that
resembled PSC both histologically and cholangiographically,
similar to the abnormalities found in the multidrug resistant
3 (mdr2) knockout mouse [44] (currently among the most
widely-utilized murine models of PSC) [45]. Interestingly,
treatment of these rats with mutanolysin, an enzyme which
breaks the 𝗽1-4 linkage of N-acetylmuramyl acid and N-
acetylglucosamine inherent to PG, but not with UDCA,
prednisone, methotrexate, or cyclosporin A, resulted in a
significant decrease in plasma aspartate aminotransferase
and liver histology scores [46]. Extending these findings, a
subsequentstudyshowedthatintraperitonealinjectionofrats
with PG resulted in (micro)cholangiographic irregularities
of smaller intrahepatic bile ducts and larger ductules, focal
areas of narrowing and fusiform sacculations, and histo-
logic evidence of bile duct destruction [47]. Another group
found that rectal administration of N-formyl L-methionine
L-leucine L-tyrosine, a chemotactic peptide produced by
E. coli which, after entering the enterohepatic circulation,BioMed Research International 3
is secreted into bile by hepatocytes, resulted in a mixed
inflammatory hepatobiliary infiltrate with predominantly
small duct cholangitis [48].
In a more recent study, it was demonstrated that repeated
inoculation of Balb/c mice with S. intermedius resulted in
nonsuppurative cholangitis and production of antibiliary
epithelial cell and antinuclear antibodies, as seen in a consid-
erableproportionofpatientswithPSC[49,50].Inadditionto
the animal models described above, several other infectious
models, including but not limited to C. parvum-inoculated
mice, demonstrate at least some biochemical, histologic,
and/orcholangiographicfeaturesofPSC,asreviewedinmore
detail elsewhere [51].
Although these models (and for that matter, no toxin-
induced, knockout, or other model) do not specifically
recapitulatetheentiretyoffindingscharacteristicofPSC,they
do provide a premise which supports the notion that hepa-
tobiliary disease in PSC may be modified, if not caused, by
aberrant microbial molecule-host interactions. This premise,
together with clinical or human cell line observations, as
will be reviewed below, has provided impetus for a growing
number of clinical studies of antibioticsin patients with PSC.
4. Human Tissue-Based Translational Studies
Supporting the PSC Microbiota Hypothesis
Given that PAMPs such as LPS, PG, and other microbially
derived molecules (e.g., lipoteichoic acid) have been pro-
posed as possible contributors or drivers of hepatobiliary
pathobiology in PSC, it is noteworthy to highlight the
body of evidence that PAMPs can be directly detected
by and induce signal transduction in cholangiocytes [24,
52–56]. Indeed, cholangiocytes are immunologically active
cells that express pathogen recognition receptors, includ-
ing nucleotide-binding oligomerization domain proteins
(NODs) and all known toll-like receptors (TLRs) [54, 55].
Binding of microbially-derived and other immunoactive lig-
ands (e.g., oxysterols) to these receptors results in signalling
through a variety of adapter proteins and pathways that
can culminate in the activation of profibroinflammatory
transcriptionfactorsandultimatelyhepatobiliaryfibrosisand
inflammation [24, 56]. As mentioned before, however, the
keyPAMPsinvolvedinactivatingsuchpathwaysinPSChave
yet to be delineated, and it remains unknown whether they
elicit disease due to increased abundance, abnormal moi-
eties/epitopes (e.g., of noncommensal, pathogenic bacteria),
exaggerated host responses, or a combination.
Several intriguing observations have been recently made
inthisregard.Thefirstisthatculturedcholangiocytesisolated
fromPSCliver(aswellasperipheralbloodmononuclearcells
[57]) have been shown to exhibit persistent hypersensitivity
(i.e., impaired immune tolerance) to pathogen recognition
receptor agonists (e.g., LPS) [58]. In addition, increased
TLR and NOD protein expression as well as activation
of the MyD88/IRAK adapter protein signalling complex
in PSC cholangiocytes have been described [58]. Of note,
circulating antibiliary epithelial cell antibodies, an area of
research that has been perhaps incompletely explored in
the pathogenesis of PSC, may account for the induction of
increased TLR expression in PSC cholangiocytes [50]. The
second intriguing observation is that not only do patients
with PSC exhibit bacterobilia [28] and detectable levels of
1 6 sr i b o s o m a lr i b o n u c l e i ca c i d( r R N A )i nb i l e[ 59, 60], but
also cholangiocytes in PSC liver sections (but not normal
livers) have been shown to accumulate LPS [61], which is
secreted into bile in a bioactive form [62, 63]. It should
be noted, though, that it remains unknown to what extent
bacterobilia or biliary 16s rRNA is the result of previous
biliaryinterventions(e.g.,endoscopicretrogradecholangiog-
raphy) that occurred after PSC had already developed. The
third observation is that genome wide association studies
have found new PSC risk loci (aside from the human
leukocyteantigencomplex)relatedtoimmunoregulationand
immune-mediated disease [64, 65]. One such example is
fucosyltransferase-2, which has been shown to influence the
microbiota, affect susceptibility to microbial infection, and
be associated with IBD (specifically Crohn’s disease) [65–
67]. More translational studies are needed to determine the
effects of both PAMPs and immunogenetic susceptibility on
cholangiocyteactivation,signaling,andtheirbearingonPSC
pathogenesis.
5. Clinical Experience with Oral Antibacterial
Agents in PSC
Since the publication of the initial case series of antibiotics in
PSC in 1959 (at that time referred to as “chronic pericholangi-
tis”)[36],anumberofstudiesofantibioticsinPSChavebeen
published, the majority being within the past 10 years [2, 68].
Three of these were prospective clinical trials (Table 1(a)):
in the first of these three, F¨ arkkil¨ ae t a l . [ 34] recruited 80
patients and randomized them to 36 months of treatment
with UDCA (15mg/kg/day) plus metronidazole (𝑛=3 9 )
or UDCA alone (𝑛=4 1 )i nad o u b l eb l i n dm a n n e r ;t h e
authors found a significant improvement in serum alkaline
phosphatase (ALK), Mayo PSC risk score, and histologic
s t a g ea n dg r a d ea sw e l la sat r e n dt o w a r dl e s sc h o l a n g i o -
graphic progression in the UDCA plus metronidazole group
after 36 months of treatment [34]. In the second clinical
trial, Silveira et al. [35] conducted an open label pilot study
wherein 16 patients with PSC were treated with minocycline
foroneyear;althoughaquarterofpatientswithdrewfromthe
study (majority due to adverse effects), those who continued
minocycline treatment experienced a significant reduction
in serum ALK and a trend toward a significant reduction
in aspartate aminotransferase and Mayo PSC risk score. In
t h et h i r da n dm o s tr e c e n tc l i n i c a lt r i a l ,T a b i b i a ne ta l .[ 25]
conducted a phase II, double blind, randomized pilot study
of vancomycin and metronidazole. Thirty-five patients with
PSC were randomized into 4 groups: low-dose vancomycin,
high-dose vancomycin, low-dose metronidazole, or high-
dose metronidazole. Although individual responses were
variable, a significant decrease in ALK at 12 weeks (the
primary endpoint) was evident in the low- and high-dose
vancomycin groups; furthermore, 2 patients in the low-
dose vancomycin group experienced normalization of ALK.4 BioMed Research International
Table 1: Previously reported results of antibacterial treatment in primary sclerosing cholangitis.
(a) Clinical trials of antibacterial treatment in primary sclerosing cholangitis
Drug (reference) Year 𝑛 Antibiotic dose Months of therapy Change after therapy
ALK AST ALT
Metronidazole (+UDCA) [34] 2004 39 600–800mg/day 36 −52.4% −41.0% −67.9%
Minocycline [35] 2009 16 200mg/day 12 −19.7% −2.8% NA
Vancomycin or metronidazole [25] 2013 18 Vancomycin 125 or 250mg qid 3 −42% −22% NA
17 Metronidazole 250 or 500mg tid 3 −10% −9% NA
(b) Case series and reports of antibacterial treatment in primary sclerosing cholangitis
Drug (reference) Year 𝑛 Antibiotic dose Months of therapy
Change after therapy
ALK AST ALT
Tetracycline [36]
∗ 1959 5 500mg/day 1–10 −45% −60% −45%
Tetracycline [27]
† 1965 5 500mg/day 48 (mean) −21% NA NA
Metronidazole [37]1 9 8 3 1 8 0 0 m g / d a y 0.25 NA
‡‡ NA
‡‡ NA
‡‡
Sulfasalazine (+UDCA) [38]
†† 1998 2
‡ — 30 and
45
−79%
−35%
−38%
−87%
−70%
−95%
Vancomycin [39]1 9 9 8 3
‡ 375–1000mg/day 9( m e a n ) N A N A −89%
Sulfasalazine (+UDCA) [40]2 0 0 2 1 5 0 m g / k g / d a y 37 NA NA −92%
Sulfasalazine [41] 2006 1 2–4.5g/day 24 −74% NA −84%
Azithromycin (+UDCA) [42]2 0 0 7 1 5 0 0 m g / d a y , 3 d a y s / w e e k 5 −72% −31% −33%
Vancomycin [43]2 0 0 8 1 4
‡ 50mg/kg/day 54 ± 43 NA NA −78%
Key: ALK: alkaline phosphatase, AST: aspartate aminotransferase; ALT: alanine aminotransferase, GGT: 𝗾-glutamyl transpeptidase; tid: three times a
day; qid: four times a day; UDCA: ursodeoxycholic acid.
Months of treatment and followup are absolute unless otherwise indicated.
∗Includes one patient who also received prednisone but was not separable from the other 4 patients.
†Does not include two patients who received prednisone.
††Does not include a third patient who also received prednisolone and mizoribine.
‡Pediatric patients.
‡‡Original casereportstatesthere wasdramaticimprovement inpatient’s condition, including defervescence,returnofappetite, andreduction ofserum
bilirubin, and after 2 weeks, becoming completely asymptomatic. Six months later, patient returned with clinical worsening, which again responded to
metronidazole.
Although patients in all 4 groups experienced significant
improvements in at least one of the secondary endpoints
(serum total bilirubin, C-reactive protein, Mayo PSC risk
score, and pruritus), adverse effects were more frequent in
the metronidazole groups. Thus, the authors recommended
(low-dose) vancomycin for further investigation, ideally in a
larger, longer-term, placebo-controlled trial [25].
Aside from these three clinical trials, there have also been
several case series and reports of oral antibacterial therapy
in PSC (Table 1(b)) [27, 36–43]. Among the most notable
o ft h e s ei sac a s es e r i e sb yK .L .C o xa n dK .M .C o xo f
three pediatric patients with PSC and IBD who experienced
normalization of liver tests and resolution of symptoms with
oralvancomycintreatment[39].Inamorerecentprospective
s e r i e sf r o mt h es a m eg r o u p ,1 4p e d i a t r i cp a t i e n t sw i t hP S C
and IBD were treated with oral vancomycin for 54 ± 43
months [43]; the authors noted normalization or significant
improvement in serum liver tests, erythrocyte sedimentation
rate,andclinicalsymptomsinnearlyallpatients.Inaddition,
when vancomycin treatment was discontinued, there was
recurrence of clinical symptoms and an increase in liver
enzymes in several patients, and retreatment again resulted
in normalization of liver enzymes [43]. Of note, there have
also been a case report and a small randomized trial of
probiotics in PSC which yielded conflicting results [69, 70].
More recently, there has also been a case report of post-LT
PSC successfully treated with oral vancomycin [71].
Although antibiotic trials thus far have been generally
s m a l la n df e wi nn u m b e r ,t a k e nc o l l e c t i v e l y ,t h e i rr e s u l t sa r e
favorable and encourage further studies of antibiotics as a
potentially safe, effective, and convenient therapy in PSC.
6. Conclusions and Future Directions
The body of basic, translational, and clinical data supporting
the PSC microbiota hypothesis continues to grow, and with
the ever-evolving developments in molecular, cellular, and
bioinformatic techniques, it is likely that more insights will
be gained. Until then, and before oral antibiotics can become
an established therapy for patients with PSC, the following
questions and considerations remain.
(1) What is the relative contribution of abnormalities
in (i) the number or type of microbially-derived
molecules as compared to (ii) the host response (i.e.,
immunogenetic susceptibility)?BioMed Research International 5
( 2 ) W h a ti st h em e c h a n i s mo fp o t e n t i a lt h e r a p e u t i c
action of antibacterial agents on PSC? Is it, for
example, related to (i) a direct effect on bacterial
(and/or other microbial) load or diversity, (ii) sec-
ondary changes in the type or amount of bacterial
components or metabolites (e.g., LPS and secondary
bile acids, resp.) in the gut and/or in the enterohep-
atic circulation, or (iii) nonantimicrobial effects, for
example, anti-inflammatory or immunoregulatory
effects, such as those ascribed to minocycline and
vancomycin, respectively [35, 72]?
(3) Which PSC patients benefit most from antibiotic
therapy,andwhataretherelevantmodifiers(e.g.,IBD
status, age, and stage)? [2]
(4) Whatantibioticanddosingregimen(e.g.,dailyversus
interrupted/alternating)willtheoreticallyprovidethe
most therapeutic effects while minimizing adverse
effects such as antibiotic resistance?
(5) Is it time for, and who will design, conduct, and fund,
alarger,longer,randomized(i.e., phaseII/III) clinical
trial of antibacterial therapy in PSC?
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